Baird initiated coverage of Cogent Biosciences with an Outperform rating and $20 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on COGT:
- Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed
- Cogent Biosciences presents nonclinical data at AACR
- Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
- Cogent Biosciences Announces Participation at Upcoming Investor Conferences
- Cogent Biosciences assumed with a Buy at H.C. Wainwright